Developmental therapeutics for myelodysplastic syndromes.

@article{Naing2006DevelopmentalTF,
  title={Developmental therapeutics for myelodysplastic syndromes.},
  author={Aung Naing and Lubomir Sokol and Alan F. List},
  journal={Journal of the National Comprehensive Cancer Network : JNCCN},
  year={2006},
  volume={4 1},
  pages={
          78-82
        }
}
The management strategy for patients with myelodysplastic syndromes (MDS) has evolved from sole reliance on supportive measures to active treatment guided by disease risks. Recent progress in understanding the molecular pathogenesis of MDS has accelerated the discovery of new therapeutic targets, and consequently launched the development of several novel therapeutics that are currently in varied stages of clinical testing. One such agent is lenalidomide, which has shown remarkable effectiveness… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

Prolonged transfusion independence and disease stability in patients with myelodysplastic syndrome responding to antithymocyte globulin [abstract

  • AJ Barrett, JJ Molldrem, Y Saunthrajarian
  • Blood
  • 1998
VIEW 2 EXCERPTS
HIGHLY INFLUENTIAL

Phase 2 study of the antiangiogenesis agent AG-013736 in patients with poor prognosis acute myeloid leukemia or myelodysplastic syndrome [abstract

  • F Giles, H Steinfeldt, WT Bellamy
  • Blood
  • 2004
VIEW 2 EXCERPTS

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.

SFCIO - 469 Scios Inc

  • Reuter CWM, MA Morgan, L Bergmann
  • Curr Opin Investig Drugs
  • 2004

Continuous oral lonafarnib (Sarasar) for the treatment of patients with myelodysplastic syndrome [abstract

  • EJ Feldman, J Cortes, T Holyoake
  • Blood
  • 2003